Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12235815 | 0.87 | KMT2A (0.64) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL14898524 | 0.85 | KMT2A (0.59) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL178731 | 0.84 | KMT2A (0.57) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL22635803 | 0.82 | KMT2A (0.56) | KMT2AEPHX2GAAFABP5CASP3 | |
| SCHEMBL114581 | 0.80 | KMT2A (0.56) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL6182639 | 0.79 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL23094050 | 0.78 | F2 (0.43) | KMT2AEPHX2 | |
| SCHEMBL3017639 | 0.76 | EPHX2 (0.60) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL13187755 | 0.76 | EPHX2 (0.60) | KMT2AEPHX2GAAFABP5FABP7 | |
| SCHEMBL13613350 | 0.76 | KMT2A (0.72) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130228-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2005-06-16 | — | — | US | claimed |
| US-20030138847-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | claimed |
| EP-1268050-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | claimed |
| WO-2001068598-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | claimed |
| WO-2024031155-A1 | RADIOPHARMACEUTICALS | AdvanCell Isotopes Pty Limited (AU) | 2024-02-15 | — | — | WO | disclosed |
| US-20230107647-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230046947-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-02-16 | — | — | US | disclosed |
| CN-115279416-A | Reactive conjugates | 德彪药业国际股份公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220185841-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2022-06-16 | — | — | US | disclosed |
| EP-4011902-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTING GROUP, AND HYDRAZINE DERIVATIVE | FUJIFILM Corporation (JP) | 2022-06-15 | — | — | EP | disclosed |
| US-11162952-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021110860-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2021-06-10 | — | — | WO | disclosed |
| US-20050130228-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2005-06-16 | — | — | US | disclosed |
| US-20040106151-A1 | Perfluoro sulfonyl halides and related species as polymer support modifiers | GE HEALTHCARE LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1352243-A2 | PERFLUORO SULFONYL HALIDES AND RELATED SPECIES AS POLYMER SUPPORT MODIFIERS | Amersham plc (GB) | 2003-10-15 | — | — | EP | disclosed |
| US-20030138847-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| US-20030124612-A1 | Perfluoro sulfonyl halides and related species as polymer support modifiers | HOLMES CHRISTOPHER (US) | 2003-07-03 | — | — | US | disclosed |
| EP-1268050-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002055026-A2 | PERFLUORO SULFONYL HALIDES AND RELATED SPECIES AS POLYMER SUPPORT MODIFIERS | AFFYMAX INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001068598-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107647-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | QPCTL, ANPEP, VIP | KMT2A 114/4885EPHX2 4536/4885GAA 2829/4885 |
| US-20220185841-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE | VIP, HRH1, NGLY1 | KMT2A 1820/4885EPHX2 2348/4885GAA 4522/4885 |
| US-11162952-B2 | Single molecule peptide sequencing | MICA, ANPEP, VIP | KMT2A 1930/4885EPHX2 4544/4885GAA 1787/4885 |
| US-20230046947-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | KMT2A 1155/4885EPHX2 2681/4885GAA 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.